Dendritic cell-based therapy in Type 1 diabetes mellitus

Authors: Phillips, Brett; Giannoukakis, Nick; Trucco, Massimo

Source: Expert Review of Clinical Immunology, Volume 5, Number 3, May 2009 , pp. 325-339(15)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Dendritic cell (DC) immunotherapy is a clinical reality. Despite two decades of considerable data demonstrating the feasibility of using DCs to prolong transplant allograft survival and to prevent autoimmunity, only now are these cells entering clinical trials in humans. Type 1 diabetes is the first autoimmune disorder to be targeted for treatment in humans using autologous-engineered DCs. This review will highlight the role of DCs in autoimmunity and the manner in which they have been engineered to treat these disorders in rodent models, either via the induction of immune hyporesponsiveness, which may be cell- and/or antigen-specific, or indirectly by upregulation of other immune cell networks.

Keywords: autoimmunity; dendritic cell; immunosuppression; immunotherapy; Type 1 diabetes

Document Type: Research article

DOI: http://dx.doi.org/10.1586/eci.09.8

Affiliations: 1: University of Pittsburgh School of Medicine, Department of Pediatrics, Division of Immunogenetics, Children's Hospital of Pittsburgh, Rangos Research Center, 530 45th Street, Pittsburgh, PA 15201, USA., Email: bep14@pitt.edu

Publication date: 2009-05-01

More about this publication?

Expert Review of Clinical Immunology provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in disease states with a strong immunologic component, such as allergic asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites